India’s Cadila to produce up to 30 mln Covid-19 vaccine doses a month, says executive

India’s Cadila to produce up to 30 mln Covid-19 vaccine doses a month, says executive
India’s Cadila to produce up to 30 mln Covid-19 vaccine doses a month, says executive

Hello and welcome to the details of India’s Cadila to produce up to 30 mln Covid-19 vaccine doses a month, says executive and now with the details

Nevin Al Sukari - Sana'a - The virus has killed nearly 100,000 Indians in May alone according to official figures. — AFP pic

Subscribe to our Telegram channel for the latest updates on news you need to know.


AHMEDABAD, May 24 — India’s Cadila Healthcare is aiming to triple monthly production of a Covid-19 vaccine candidate to as many as 30 million doses, its managing director said today, as the country battles a massive wave of infections.

The virus has killed nearly 100,000 Indians in May alone according to official figures, although experts say actual numbers are likely many times higher. India’s Covid-19 death toll surged past 300,000 on Monday, health ministry data showed.

India is also facing a shortage of vaccines. Weekly vaccinations have fallen from a peak of nearly 25 million doses in early April to about 9 million. The government has pledged to make 2.67 billion doses available this year.

Cadila, headquartered in Ahmedabad in western India, is looking to increase monthly production of its vaccine candidate ZyCoV-D to up to 30 million doses in four to five months, from 10 million now, its managing director, Sharvil Patel, said in text messages to Reuters.

Reuters reported last month Cadila was seeking emergency use authorisation for the shot from India’s regulators in May or June.

“We still think we should be able to submit (the vaccine for emergency use authorisation) in May,” Patel said on Monday.

The company will use both in-house capacity as well as third-party manufacturers to boost production, he said.

ZyCoV-D is a DNA plasmid vaccine, which uses a portion of the genetic code - DNA or RNA - in the virus to stimulate an immune response.

It is undergoing late-stage trials in nearly 30,000 adults after being found safe and immunogenic in earlier studies. It is meant to be given in three doses but Cadila is also doing trials on a two-dose regimen, Patel has said previously. — Reuters

These were the details of the news India’s Cadila to produce up to 30 mln Covid-19 vaccine doses a month, says executive for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

NEXT Deadly heat wave slams Canada, US